期刊文献+

环氧化酶在大鼠缺血心肌血管生成及内皮祖细胞动员中的作用 被引量:1

The role of cyclooxygenase on angiogenesis and endothelial progenitor cell mobilization in rat ischemic myocardium
原文传递
导出
摘要 目的探讨环氧化酶(COX)1、2在缺血心肌血管生成和内皮祖细胞动员中的作用及机制。方法实验大鼠随机分为心肌缺血加选择性 COX2抑制剂罗非昔布组、心肌缺血加选择性 COX1抑制剂 valeryl salicylate(VS)组和单纯心肌缺血组。心肌缺血组于术后1周取血浆测血管内皮生长因子(VEGF),外周血分离单个核细胞培养计数内皮祖细胞和缺血心肌组织检测缺氧诱导因子-1αmRNA,28天后取缺血区心肌免疫组化法测毛细血管密度。结果心肌缺血加罗非昔布组与单纯心肌缺血组、心肌缺血加 VS 组比较,血浆 VEGF 水平、循环血内皮祖细胞计数、缺血心肌毛细血管密度和缺氧诱导因子-1α mRNA 表达均显著减少(P<0.05),其余指标两组差异无统计学意义。结论COX2在心肌缺血时内皮祖细胞动员和缺血心肌血管生成中起重要作用,其可能机制与增加缺氧诱导因子-1α和 VEGF 的表达有关,而 COX1没有作用。 Objective To investigate the effect of COX1 and COX2 on angiogenesis and endothelial progenitor cell mobilization in rats with experimental myocardial infarction (MI). Methods The rats were randomly divided into 3 groups: MI group, MI plus rofecoxib group and MI plus valeryl salicylate group. At the 7th day after operation, circulating EPCs, plasma VEGF and HIF-1α mBNA of ischemic myocardium were measured. At the 28th day post operation, capillary densities were also measured in ischemic myocardium. Result Compared with the MI group and the MI plus valeryl salicylate group, circulating EPCs, plasma VEGF, HIF-1α mRNA and capillary densities of ischemic myocardium were all decreased in MI plus rofecoxib group. Conclusion The present study revealed that COX2 play an important role with angiogenesis and endothelial progenitor cell mobilization in rat with experimental MI by modulating expression of VEGF and HIF-1α .
出处 《中华心血管病杂志》 CAS CSCD 北大核心 2006年第9期833-836,共4页 Chinese Journal of Cardiology
基金 国家自然科学基金(30270568)
关键词 心肌缺血 氧化还原酶类 新生血管化 生理性 干细胞 Myocardial ischemia Oxidoreductases Neovascularization, physiologic Stem cells
  • 相关文献

参考文献18

  • 1Buerkle MA,Lehrer S,Sohn HY,et al.Selective inhibition of cyclooxygenase-2 enhances platelet adhesion in hamster arterioles in vivo.Circulation,2004,110:2053-2059.
  • 2Mukherjee D.Selective cyclooxygenase-2(COX-2) inhibitors and potential risk of cardiovascular events.Biochem Pharmacol,2002,63:817-821.
  • 3Solomon DH,Schneeweiss S,Glynn RJ,et al.Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.Circulation,2004,109:2068-2073.
  • 4Mamdani M,Juurlink DN,Lee DS,et al.Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients:a population-based cohort study.Lancet,2004,363:1751-1756.
  • 5Fosslien E.Review:molecular pathology of cyclooxygenase-2 incancer-induced angiogenesis.Ann Clin Lab Sci,2001,31:325-348.
  • 6Yoshida S,Amano H,Hayashi I,et al.COX-2/VEGF-dependent facilitation of tumor-associated angiogenesis and tumor growth in vivo.Lab Invest,2003,83:1385-1394.
  • 7Hill JM,Zalos G,Halcox JP,et al.Circulating endothelial progenitor cells,vascular function,and cardiovascular risk.N Engl J Med,2003,348:593-600.
  • 8Kalka C,Masuda H,Takahashi T,et al.Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization.Proc Natl Acad Sci U S A,2000,97:3422-3427.
  • 9Dimmeler S,Aicher A,Vasa M,et al.HMG-CoA reductase inhibitors(statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway.J Clin Invest,2001,108:391-397.
  • 10Vasa M,Fichtlscherer S,Aicher A,et al.Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease.Circ Res,2001,89:E1-E7.

二级参考文献23

  • 1Laham R, Simons M. Therapeutic angiogenesis in myocardial ischemia.In: Ware JA, Simons M,eds. Angiogenesis and Cardiovascular Disease. Oxford: Oxford University Press, 1999.289-320.
  • 2Morishita R, Aoki M, Kaneda Y, et al. Gene therapy in vascular medicine: recent advances and future perspectives. Pharmacol Ther,2001,91:105-114.
  • 3Li JJ, Ueno H, Yamamoto H, et al. Quantitative analysis of repeat adenovirus mediated gene transfer into injured canine femoral arteries. Arterioscler Thromb Vasc Biol,1995,15:2246-2253.
  • 4Lawrie A, Brisken AF, Francis SE, et al. Microbubble-enhanced ultrasound for vascular gene delivery. Gene therapy, 2000, 7:2023-2027.
  • 5Folkman J. Angiogenic therapy of human heart. Circulation, 1998,97:628-629.
  • 6Isner JM, Piecezk A, Schainfeld R, et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patients with ischemic limb. Lancet, 1996, 348:370-374.
  • 7Rosengart TK, Lee LY, Patel SR, et al. Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Ann Sur
  • 8Yancopoulos GD, Davis S, Gale NW. et al. Vascular-specific growth factors and blood vessel formation. Nature, 2000, 407:242-248.
  • 9Kornowski R, Fuchs S, Leon MB,et al. Delivery strategies to achieve therapeutic myocardial angiogenesis. Circulation, 2000, 101:454-458.
  • 10Unger EC, McCreery TP, Sweilzer RH. Ultrasound enhance gene expression of liposomal transfection. Invest Radiol, 1997, 32:723-727.

共引文献28

同被引文献6

引证文献1

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部